LOGIN  |  REGISTER
Cue Biopharma
Assertio

NeuroPace to Participate in Upcoming Investor Conferences

August 24, 2023 | Last Trade: US$11.53 0.39 3.50
  • Wells Fargo 2023 Healthcare Conference 
  • Morgan Stanley 21st Annual Global Healthcare Conference 
  • Lake Street Capital Markets 7th Annual Best Ideas Growth Conference 

MOUNTAIN VIEW, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced its participation in the following upcoming investor conferences:

  • Management will host 1x1 meetings at the Wells Fargo 2023 Healthcare Conference on Thursday, September 7, 2023, in Everett, MA.
  • Joel Becker, CEO, and Rebecca Kuhn, CFO, will participate in a fireside chat discussion and host 1x1 meetings at the Morgan Stanley 21st Annual Global Healthcare Conference at 9:30 AM ET on Wednesday, September 13, 2023, in New York, NY.
  • Management will host 1x1 meetings at the Lake Street Capital Markets 7th Annual Best Ideas Growth Conference on Thursday, September 14, 2023, in New York, NY

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB